Published on in Vol 5 (2024)
Preprints (earlier versions) of this paper are
available at
https://www.medrxiv.org/content/10.1101/2023.11.19.23298750v1, first published
.
![Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis](https://asset.jmir.pub/assets/a276ea474421aa1c9c6cbdd3da3a5a54.png 480w,https://asset.jmir.pub/assets/a276ea474421aa1c9c6cbdd3da3a5a54.png 960w,https://asset.jmir.pub/assets/a276ea474421aa1c9c6cbdd3da3a5a54.png 1920w,https://asset.jmir.pub/assets/a276ea474421aa1c9c6cbdd3da3a5a54.png 2500w)
There are currently no tweets available for this article within the specified range.